Taken together, our results demonstrate that GATA3-AS1 could be clinically applicable as a predictive biomarker for NAC efficacy in luminal B breast cancer patients according to an RT–qPCR analysis of paraffin-embedded tissues. This evidence concerns the gene GATA3 and breast carcinoma.